Viewing Study NCT01186861

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 12:38 PM

Ignite Modification Date: 2025-12-28 @ 9:24 AM

Study NCT ID: NCT01186861

Status: COMPLETED

Last Update Posted: 2025-11-18

First Post: 2010-08-19

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Sponsor: Astellas Pharma Inc

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module